Cytodyn Inc (CYDY)

[Jdeezy]

Agree. The primary thing that stood out when I read the article the other day, is not only were they in severe condition but they were extremely high risk patients.

What happens if they had no previous underlying condition? one could assume even better results since these were patients in worst case scenario, severe condition and on other medications for underlying conditions in most cases. This is important because future studies will include less severe patients and results should be dramatically better in theory.

"At Montefiore Medical Center, we identified 36 consecutive adult kidney-transplant recipients who tested positive for Covid-19 between March 16 and April 1, 2020. A total of 26 recipients (72%) were male, and the median age was 60 years (range, 32 to 77)"

Six severely ill patients received the CCR5 inhibitor leronlimab (PRO 140, CytoDyn) on a compassionate-use basis, and 2 received the interleukin-6 receptor antagonist tocilizumab. Interleukin-6 levels were very elevated (range, 83 to 8175 pg per milliliter) when leronlimab was initiated (on day 0) in the 5 patients with elevated interleukin-6 levels; these levels decreased markedly 3 days later (range, 37 to 2022 pg per milliliter) (see Table S2 in the Supplementary Appendix). However, only the 1 patient who had the lowest interleukin-6 level (at 83 pg per milliliter) remained in stable condition without intubation.